Difference between revisions of "Example orders for Docetaxel (Taxotere) in non-small cell lung cancer"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "/m2 " to "/m<sup>2</sup> ")
m (Text replacement - " " to " ")
 
(13 intermediate revisions by 2 users not shown)
Line 1: Line 1:
'''Use of this site is subject to you reading and agreeing with the terms set forth in the [[HemOnc.org_-_A_Hematology_Oncology_Wiki:General_disclaimer|disclaimer]].'''
+
<!--'''Use of this site is subject to you reading and agreeing with the terms set forth in the [[HemOnc.org_-_A_Hematology_Oncology_Wiki:General_disclaimer|disclaimer]]. If this is your first time visiting, we suggest you read the [[tutorial]].'''-->
  
 
Remember that example order sets that may contain additional information about supportive medications, suggestions for monitoring, hydration, and pre-treatment screening information for chemotherapy regimens are purely anecdotal, provided only as examples of what some other providers may be using, and are typically not based on references in the primary literature.
 
Remember that example order sets that may contain additional information about supportive medications, suggestions for monitoring, hydration, and pre-treatment screening information for chemotherapy regimens are purely anecdotal, provided only as examples of what some other providers may be using, and are typically not based on references in the primary literature.
Line 9: Line 9:
 
===Example regimen #1===
 
===Example regimen #1===
 
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV on day 1  
 
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV on day 1  
**Administer over 30-60 minutes. Use non-DEHP tubing/paclitaxel tubing.
+
**Administer over 30-60 minutes. Use non-DEHP tubing/paclitaxel tubing.
  
'''21-day cycles, given until progression of disease or unacceptable toxicity'''
+
'''21-day cycles'''
  
Supportive medications:
+
====Supportive therapy====
*Prochlorperazine (Compazine) 10 mg PO x 1 prn nausea
+
*Prochlorperazine (Compazine) 10 mg PO x 1 prn nausea  
*[[Dexamethasone (Decadron)]] 8 mg PO BID the day before, day of, and day after chemotherapy
+
*[[Dexamethasone (Decadron)]] 8 mg PO twice per day the day before, day of, and day after chemotherapy
  
 
Hydration:
 
Hydration:
Line 22: Line 22:
 
Monitoring:
 
Monitoring:
 
*On day 1 of each cycle: CBC with differential, absolute neutrophil count (ANC), BUN/Cr, alk phos, AST, ALT, total bilirubin, carcinoembryonic antigen
 
*On day 1 of each cycle: CBC with differential, absolute neutrophil count (ANC), BUN/Cr, alk phos, AST, ALT, total bilirubin, carcinoembryonic antigen
*On cycle 1 day 10, check nadir CBC with differential, absolute neutrophil count (ANC). Need for further nadir count checks to be determined by degree of cytopenias.
+
*On cycle 1 day 10, check nadir CBC with differential, absolute neutrophil count (ANC). Need for further nadir count checks to be determined by degree of cytopenias.
 
*Assess for response with CT scan every 3+ cycles depending on symptoms
 
*Assess for response with CT scan every 3+ cycles depending on symptoms
  
 
Outpatient medications:
 
Outpatient medications:
 
*[[Dexamethasone (Decadron)]] as described above
 
*[[Dexamethasone (Decadron)]] as described above
*Lorazepam (Ativan) 0.5 mg PO Q6H prn anxiety, insomnia, nausea
+
*Lorazepam (Ativan) 0.5 mg PO every 6 hours prn anxiety, insomnia, nausea
*Ondansetron (Zofran) 4 mg PO Q6H prn nausea
+
*Ondansetron (Zofran) 4 mg PO every 6 hours prn nausea
  
 
'''Clinical scenario & comments:'''
 
'''Clinical scenario & comments:'''
*60 year-old lady with stage IV adenocarcinoma of the lung, s/p treatment with first-line therapy for metastatic disease with [[Non-small cell lung cancer#Carboplatin_monotherapy_.26_Pemetrexed_.28Alimta.29|Carboplatin (Paraplatin) & Pemetrexed (Alimta)]], with good response. Progressed after maintenance therapy with Pemetrexed (Alimta).
+
*60 year-old lady with stage IV adenocarcinoma of the lung, s/p treatment with first-line therapy for metastatic disease with [[Non-small cell lung cancer#Carboplatin_monotherapy_.26_Pemetrexed_.28Alimta.29|Carboplatin (Paraplatin) & Pemetrexed (Alimta)]], with good response. Progressed after maintenance therapy with Pemetrexed (Alimta).
  
 
===Example regimen #2 - dose reduction & neulasta for pancytopenia===
 
===Example regimen #2 - dose reduction & neulasta for pancytopenia===
 
*[[Docetaxel (Taxotere)]] 60 mg/m<sup>2</sup> IV on day 1  
 
*[[Docetaxel (Taxotere)]] 60 mg/m<sup>2</sup> IV on day 1  
**Administer over 30-60 minutes. Use non-DEHP tubing/paclitaxel tubing.
+
**Administer over 30-60 minutes. Use non-DEHP tubing/paclitaxel tubing.
  
'''21-day cycles, given until progression of disease or unacceptable toxicity'''
+
'''21-day cycles'''
  
Supportive medications:
+
====Supportive therapy====
 
*[[Pegfilgrastim (Neulasta)]] 6 mg SC x1 on day 2, 24 hours after completion of day 1 chemotherapy
 
*[[Pegfilgrastim (Neulasta)]] 6 mg SC x1 on day 2, 24 hours after completion of day 1 chemotherapy
*Prochlorperazine (Compazine) 10 mg PO x 1 prn nausea
+
*Prochlorperazine (Compazine) 10 mg PO x 1 prn nausea  
*[[Dexamethasone (Decadron)]] 8 mg PO BID the day before, day of, and day after chemotherapy
+
*[[Dexamethasone (Decadron)]] 8 mg PO twice per day the day before, day of, and day after chemotherapy
  
 
Hydration:
 
Hydration:
Line 49: Line 49:
 
Monitoring:
 
Monitoring:
 
*On day 1 of each cycle: CBC with differential, absolute neutrophil count (ANC), BUN/Cr, alk phos, AST, ALT, total bilirubin, carcinoembryonic antigen
 
*On day 1 of each cycle: CBC with differential, absolute neutrophil count (ANC), BUN/Cr, alk phos, AST, ALT, total bilirubin, carcinoembryonic antigen
*Once on day 10-14, check nadir CBC with differential, absolute neutrophil count (ANC). Transfuse RBCs as needed.
+
*Once on day 10-14, check nadir CBC with differential, absolute neutrophil count (ANC). Transfuse RBCs as needed.
 
*Assess for response with CT scan every 3+ cycles depending on symptoms
 
*Assess for response with CT scan every 3+ cycles depending on symptoms
  
 
Outpatient medications:
 
Outpatient medications:
 
*[[Dexamethasone (Decadron)]] as described above
 
*[[Dexamethasone (Decadron)]] as described above
*Lorazepam (Ativan) 0.5 mg PO Q6H prn anxiety, insomnia, nausea
+
*Lorazepam (Ativan) 0.5 mg PO every 6 hours prn anxiety, insomnia, nausea
*Ondansetron (Zofran) 4 mg PO Q6H prn nausea
+
*Ondansetron (Zofran) 4 mg PO every 6 hours prn nausea
  
 
'''Clinical scenario & comments:'''
 
'''Clinical scenario & comments:'''
*72 year-old lady with stage IV adenocarcinoma of the lung with bony metastases and history of pathologic fracture, s/p treatment with first-line therapy for metastatic disease with [[Non-small cell lung cancer#Carboplatin_monotherapy_.26_Pemetrexed_.28Alimta.29|Carboplatin (Paraplatin) & Pemetrexed (Alimta)]], who initially responded but them progressed on CT imaging after cycle 5 of therapy. Cycle 1 of therapy was given as above in example #1, but due to significant neutropenia, anemia, and thrombocytopenia (50-60) at nadir blood count, Docetaxel (Taxotere) was dose reduced as above, and Pegfilgrastim (Neulasta) added. In later cycles, neutropenia was not an issue, RBC transfusion need was minimal, and platelet counts were adequate for treatment.
+
*72 year-old lady with stage IV adenocarcinoma of the lung with bony metastases and history of pathologic fracture, s/p treatment with first-line therapy for metastatic disease with [[Non-small cell lung cancer#Carboplatin_monotherapy_.26_Pemetrexed_.28Alimta.29|Carboplatin (Paraplatin) & Pemetrexed (Alimta)]], who initially responded but them progressed on CT imaging after cycle 5 of therapy. Cycle 1 of therapy was given as above in example #1, but due to significant neutropenia, anemia, and thrombocytopenia (50-60) at nadir blood count, Docetaxel (Taxotere) was dose reduced as above, and Pegfilgrastim (Neulasta) added. In later cycles, neutropenia was not an issue, RBC transfusion need was minimal, and platelet counts were adequate for treatment.
  
 
[[Category:Example chemotherapy order sets]]
 
[[Category:Example chemotherapy order sets]]

Latest revision as of 02:05, 1 June 2023


Remember that example order sets that may contain additional information about supportive medications, suggestions for monitoring, hydration, and pre-treatment screening information for chemotherapy regimens are purely anecdotal, provided only as examples of what some other providers may be using, and are typically not based on references in the primary literature.


Docetaxel (Taxotere)

Original references may be found at Docetaxel (Taxotere)

Example regimen #1

  • Docetaxel (Taxotere) 75 mg/m2 IV on day 1
    • Administer over 30-60 minutes. Use non-DEHP tubing/paclitaxel tubing.

21-day cycles

Supportive therapy

  • Prochlorperazine (Compazine) 10 mg PO x 1 prn nausea
  • Dexamethasone (Decadron) 8 mg PO twice per day the day before, day of, and day after chemotherapy

Hydration:

  • 500 ml NS at KVO rate. Use as running IV for chemotherapy infusion. Give up to 500 ml NS.

Monitoring:

  • On day 1 of each cycle: CBC with differential, absolute neutrophil count (ANC), BUN/Cr, alk phos, AST, ALT, total bilirubin, carcinoembryonic antigen
  • On cycle 1 day 10, check nadir CBC with differential, absolute neutrophil count (ANC). Need for further nadir count checks to be determined by degree of cytopenias.
  • Assess for response with CT scan every 3+ cycles depending on symptoms

Outpatient medications:

  • Dexamethasone (Decadron) as described above
  • Lorazepam (Ativan) 0.5 mg PO every 6 hours prn anxiety, insomnia, nausea
  • Ondansetron (Zofran) 4 mg PO every 6 hours prn nausea

Clinical scenario & comments:

  • 60 year-old lady with stage IV adenocarcinoma of the lung, s/p treatment with first-line therapy for metastatic disease with Carboplatin (Paraplatin) & Pemetrexed (Alimta), with good response. Progressed after maintenance therapy with Pemetrexed (Alimta).

Example regimen #2 - dose reduction & neulasta for pancytopenia

  • Docetaxel (Taxotere) 60 mg/m2 IV on day 1
    • Administer over 30-60 minutes. Use non-DEHP tubing/paclitaxel tubing.

21-day cycles

Supportive therapy

  • Pegfilgrastim (Neulasta) 6 mg SC x1 on day 2, 24 hours after completion of day 1 chemotherapy
  • Prochlorperazine (Compazine) 10 mg PO x 1 prn nausea
  • Dexamethasone (Decadron) 8 mg PO twice per day the day before, day of, and day after chemotherapy

Hydration:

  • 500 ml NS at KVO rate. Use as running IV for chemotherapy infusion. Give up to 500 ml NS.

Monitoring:

  • On day 1 of each cycle: CBC with differential, absolute neutrophil count (ANC), BUN/Cr, alk phos, AST, ALT, total bilirubin, carcinoembryonic antigen
  • Once on day 10-14, check nadir CBC with differential, absolute neutrophil count (ANC). Transfuse RBCs as needed.
  • Assess for response with CT scan every 3+ cycles depending on symptoms

Outpatient medications:

  • Dexamethasone (Decadron) as described above
  • Lorazepam (Ativan) 0.5 mg PO every 6 hours prn anxiety, insomnia, nausea
  • Ondansetron (Zofran) 4 mg PO every 6 hours prn nausea

Clinical scenario & comments:

  • 72 year-old lady with stage IV adenocarcinoma of the lung with bony metastases and history of pathologic fracture, s/p treatment with first-line therapy for metastatic disease with Carboplatin (Paraplatin) & Pemetrexed (Alimta), who initially responded but them progressed on CT imaging after cycle 5 of therapy. Cycle 1 of therapy was given as above in example #1, but due to significant neutropenia, anemia, and thrombocytopenia (50-60) at nadir blood count, Docetaxel (Taxotere) was dose reduced as above, and Pegfilgrastim (Neulasta) added. In later cycles, neutropenia was not an issue, RBC transfusion need was minimal, and platelet counts were adequate for treatment.